Loading...
Ligand Pharmaceuticals Incorporated
LGND•NASDAQ
Healthcare
Biotechnology
$135.83
$3.00(2.26%)
Ligand Pharmaceuticals Incorporated (LGND) Financial Performance & Income Statement Overview
Review Ligand Pharmaceuticals Incorporated’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
27.28%
↑ 27.28%
Operating Income Growth
-289.30%
↓ 289.30%
Net Income Growth
-107.73%
↓ 107.73%
Operating Cash Flow Growth
95.75%
↑ 95.75%
Operating Margin
-34.06%
↓ 34.06%
Gross Margin
82.73%
↑ 82.73%
Net Profit Margin
-73.07%
↓ 73.07%
ROE
-16.36%
↓ 16.36%
ROIC
-7.30%
↓ 7.30%
Ligand Pharmaceuticals Incorporated (LGND) Income Statement & Financial Overview
Review Ligand Pharmaceuticals Incorporated's (LGND) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $42.81M | $51.81M | $41.53M | $30.98M |
| Cost of Revenue | $2.84M | $12.49M | $11.16M | $11.07M |
| Gross Profit | $39.98M | $39.32M | $30.37M | $19.91M |
| Gross Profit Ratio | $0.93 | $0.76 | $0.73 | $0.64 |
| R&D Expenses | $4.42M | $5.67M | $5.35M | $5.97M |
| SG&A Expenses | $25.61M | $24.48M | $19.12M | $10.95M |
| Operating Expenses | $49.61M | $36.17M | $22.98M | $16.92M |
| Total Costs & Expenses | $52.45M | $48.67M | $34.14M | $27.99M |
| Interest Income | $1.93M | $1.35M | $2.76M | $2.02M |
| Interest Expense | $883000.00 | $741000.00 | $1.27M | $141000.00 |
| Depreciation & Amortization | $8.63M | $8.99M | $9.36M | $9.24M |
| EBITDA | -$29.10M | $3.14M | -$54.77M | $12.23M |
| EBITDA Ratio | -$0.68 | $0.06 | -$1.32 | $0.39 |
| Operating Income | -$9.64M | $3.14M | $7.39M | $2.99M |
| Operating Income Ratio | -$0.23 | $0.06 | $0.18 | $0.10 |
| Other Income/Expenses (Net) | -$29.56M | -$9.48M | -$46.29M | $110.46M |
| Income Before Tax | -$39.20M | -$6.34M | -$65.39M | $113.45M |
| Income Before Tax Ratio | -$0.92 | -$0.12 | -$1.57 | $3.66 |
| Income Tax Expense | -$8.11M | $833000.00 | -$13.48M | $27.31M |
| Net Income | -$31.09M | -$7.17M | -$51.91M | $86.14M |
| Net Income Ratio | -$0.73 | -$0.14 | -$1.25 | $2.78 |
| EPS | -$1.64 | -$0.39 | -$2.88 | $4.86 |
| Diluted EPS | -$1.64 | -$0.39 | -$2.88 | $4.75 |
| Weighted Avg Shares Outstanding | $18.97M | $18.42M | $18.03M | $17.73M |
| Weighted Avg Shares Outstanding (Diluted) | $18.97M | $18.42M | $18.03M | $18.12M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan